Page last updated: 2024-09-05

ly 293111 and clobetasol

ly 293111 has been researched along with clobetasol in 1 studies

Compound Research Comparison

Studies (ly 293111)	Trials (ly 293111)	Recent Studies (post-2010) (ly 293111)	Studies (clobetasol)	Trials (clobetasol)	Recent Studies (post-2010) (clobetasol)
38	9	6	1,532	389	593

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kooijmans-Otero, ME; Mommers, JM; Parker, GL; van de Kerkhof, PC; Van Rossum, MM	1

Trials

1 trial(s) available for ly 293111 and clobetasol

Article	Year
VML 295 (LY-293111), a novel LTB4 antagonist, is not effective in the prevention of relapse in psoriasis. The British journal of dermatology, 2000, Volume: 142, Issue:2 Topics: Administration, Topical; Anti-Inflammatory Agents; Benzoates; Clobetasol; Drug Therapy, Combination; Flow Cytometry; Glucocorticoids; Humans; Leukotriene Antagonists; Leukotriene B4; Psoriasis; Recurrence; Severity of Illness Index	2000

Article

Year

VML 295 (LY-293111), a novel LTB4 antagonist, is not effective in the prevention of relapse in psoriasis.

The British journal of dermatology, 2000, Volume: 142, Issue:2

Topics: Administration, Topical; Anti-Inflammatory Agents; Benzoates; Clobetasol; Drug Therapy, Combination; Flow Cytometry; Glucocorticoids; Humans; Leukotriene Antagonists; Leukotriene B4; Psoriasis; Recurrence; Severity of Illness Index

2000